Chepstow-based Creo Medical Group plc has entered into two further framework distribution agreements to provide clinical training and market seeding across the Spanish, Belgian, Dutch and Luxembourg markets.

The agreements cover Creo's Croma advance energy platform and Speedboat products, ahead of their full commercial launch in 2019.

Creo is a medical device company focused on the emerging field of surgical endoscopy. It is based at Beaufort Park, Chepstow.

The company has signed an agreement with Spanish distributor JJP Hospitalaria SL covering the Spanish market and an agreement with Netherlands-based distributor Stinnow medical to cover Belgium, the Netherlands and Luxembourg.

Continuing Creo's education-led commercial strategy, both distributors will collaborate with Creo over an 18-month period to advance the roll out of its clinical education programme.

The programme will educate key clinicians in the use of Speedboat and the Croma platform with the aim of ensuring quality control and best patient outcomes.

These agreements follow on from similar agreements covering Asia-Pacific as well as the UK and South Africa.

Craig Gulliford, chief executive officer of Creo, said: “Entering mainland Europe is an important milestone for Creo as we work towards commercialisation of our lead product, Speedboat, powered by our CROMA advanced energy platform.

"This will be the first time Creo has shipped products to these areas which we believe will be key markets for the company.

"The signing of these agreements is in line with our strategy to grow our distribution network and reputation both in Europe and worldwide and will position us well as we strive to advance the emerging field of surgical endoscopy.”